GlassScriptPhysician profile
Robert H Wiskind
NPI 1205909850
$20,811.93
in general payments reported to CMS, 2019-2025
22 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $141 · 2021: $414 · 2022: $418 · 2023: $343 · 2024: $351 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $18K · Food and Beverage: $1,115 · Long Term Medical Supply Or Device Loan: $20.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $18,424.21 |
| Food and Beverage | $1,114.59 |
| Long Term Medical Supply Or Device Loan | $20.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $18,424.21 | 2025 | |
| Supernus Pharmaceuticals, INC. | $296.56 | 2021-2024 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $295.32 | 2021-2025 | |
| Tris Pharma INC | $251.16 | 2019-2024 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $218.73 | 2023-2025 | |
| Pfizer INC. | $174.09 | 2019-2025 | |
| Kaleo, INC. | $153.03 | 2019-2024 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $135.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $111.91 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $111.74 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $108.35 | 2021-2024 | Doc Band |
| Seqirus USA INC | $102.30 | 2024-2025 | Flucelvax |
| Adlon Therapeutics L.P. | $76.98 | 2020-2021 | |
| Glaxosmithkline, LLC. | $69.48 | 2019-2025 | Bexsero |
| Neos Therapeutics, LP | $63.08 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $59.48 | 2023-2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $42.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $41.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $20.99 | 2025 | |
| Baxter Healthcare | $20.63 | 2024 | Hillrom - Spot Vital Signs 4400 Device |
| Eyevance Pharmaceuticals LLC | $17.48 | 2021 | |
| Shire North American Group INC | $17.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wiskind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.